Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gene Express, a molecular diagnostic company, has signed a definitive agreement with AbaStar MDx to license Gene Express's SEM Center and StaRT-PCR Technology.
Subscribe to our email newsletter
AbaStar MDx will utilize Gene Express’s proprietary technology in the development and commercialization of genetic biomarkers for the accurate diagnoses of neurological and psychological disorders.
The combination of Gene Express’s StaRT-PCR technology with AbaStar MDx’s RNA biomarker signature will lead to the development of diagnostic tests, run from a simple blood sample that will provide results in a day.
Over the next several years, Gene Express and AbaStar MDx will be undertaking activities to develop these genetic tests and bring them to market. Such activities will include the creation of several hundred gene standards, screening of gene expression profiles and the creation of validated standardized mixtures of internal standards for clinical trial use.
Once the StaRT-PCR signatures are validated AbaStar MDx will introduce these diagnostics to the market. The overall value of the transaction could potentially exceed $100 million.
Jonathan Rowe, COO of Gene Express, said: “The alliance between AbaStar MDx and Gene Express is an important leap in identifying molecular diagnostic tests for the diagnosis of psychiatric disorders. The combination of AbaStar’s research with Gene Express’s technology will lead to high quality, specific, sensitive and comparable tests that can be used to bring the right care to the right patients.”